证券代码：688602 证券简称：康鹏科技 公告编号：2025-050 上海康鹏科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 担保对象及基本情况 担保对象 实际为其提供的担保余额 0.00 万元 被担保人名称 中央硝子株式会社 本次担保金额 3,600.00 万元 是否在前期预计额度内 □是 □否 ?不适用：_________ 本次担保是否有反担保 □是 ?否 □不适用：_________ □对合并报表外单位担保金额达到或超过最近一期 经审计净资产 30%的情况下 □对资产负债率超过 70%的单位提供担保 其他风险提示（如有） 无 ? 累计担保情况 对外担保逾期的累计金额（万元） 0.00 截至本公告日上市公司及其控股子公 司对外担保总额（万元） 对外担保总额占上市公司最近一期经 审计净资产的比例（%） □对外担保总额超过最近一期经审计净资产 100% □担保金额超过上市公司最近一期经审计净资产 特别风险提示（如有请勾选） 一、反担保情况概述 （一）反担保的基本情况 上海康鹏科技股份有限 ...

Core Points - The article outlines the establishment and operational framework of Shanghai Chemspec Corporation, including its legal basis, registration details, and corporate governance structure [1][2][3]. Chapter Summaries Chapter 1: General Provisions - The company aims to protect the rights of shareholders, employees, and creditors while adhering to relevant laws and regulations [1]. - The company is established as a joint-stock company under Chinese law, with a registered capital of RMB 519.375 million [2]. Chapter 2: Business Objectives and Scope - The company's business objectives include the production and sale of display materials, new energy batteries, electronic materials, pharmaceuticals, and other chemicals [4]. - The approved business scope includes technology services, new chemical substance production, and import/export activities [4]. Chapter 3: Shares - The company issues shares in the form of stocks, with all issued shares being ordinary shares [5][7]. - The total number of shares issued is 51.9375 million, with a par value of RMB 1 per share [7]. Chapter 4: Shareholders and Shareholder Meetings - Shareholders have rights proportional to their shareholdings, including profit distribution and participation in shareholder meetings [12]. - The company must maintain a shareholder register, documenting shareholder details and shareholdings [33]. Chapter 5: Board of Directors - The board of directors is responsible for the company's governance and decision-making processes, ensuring compliance with laws and regulations [14]. - Directors are accountable for their actions and can be held liable for damages caused to the company [40]. Chapter 6: Senior Management - Senior management includes the general manager, deputy general managers, and other key personnel, who are responsible for executing company affairs [12]. Chapter 7: Financial Accounting System, Profit Distribution, and Auditing - The company must adhere to a financial accounting system that ensures transparency and accountability in financial reporting [7]. Chapter 8: Notices and Announcements - The company is required to issue notices and announcements in accordance with legal and regulatory requirements [8]. Chapter 9: Mergers, Divisions, Capital Increases, Reductions, Dissolution, and Liquidation - The company can engage in mergers, capital increases, and other structural changes as per legal provisions [9]. Chapter 10: Amendments to the Articles - Amendments to the company's articles of association must be approved by the shareholders [10]. Chapter 11: Supplementary Provisions - The articles serve as a binding document for the company, shareholders, and management, outlining their rights and obligations [11].

上海康鹏科技股份有限公司独立董事工作制度 位有5年以上全职工作经验。 第五条 独立董事应当按照中国证券监督管理委员会（以下简称"中国证监 会"）的要求，参加中国证监会及其授权机构所组织的培训。 第二章 独立董事的任职条件 第六条 担任公司独立董事应当符合下列基本条件： （一）根据法律、法规及其他有关规定，具备担任上市公司董事的资格； （二）具有本制度第七条所要求的独立性； （三）具备上市公司运作的基本知识，熟悉相关法律、法规、规章及规则； （四）具有五年以上履行独立董事职责所必须的法律、会计或者经济等工作 经验； （五）具有良好的个人品德，不存在重大失信等不良记录； （六）法律、行政法规、中国证监会、上海证券交易所和《公司章程》规定 的其他条件。 独立董事原则上最多在三家境内上市公司担任独立董事，并应当确保有足够 的时间和精力有效地履行独立董事的职责。 第七条 独立董事必须具有独立性，下列人员不得被提名担任独立董事： （一）在公司或者其附属企业任职的人员及其配偶、父母、子女、主要社会 关系； （二）直接或间接持有公司已发行股份1%以上或者是公司前十名股东中的 自然人股东及其配偶、父母、子女； （三）在直接或间 ...

Group 1 - The company reported a revenue of 436 million yuan for the first half of 2025, representing a year-on-year growth of 27.94% [1] - The net profit attributable to shareholders reached 31.02 million yuan, showing a significant year-on-year increase of 257.08% [1] - The company's net profit after deducting non-recurring items was 23.36 million yuan, marking a turnaround from losses to profitability compared to the previous year [1] - The basic earnings per share stood at 0.06 yuan [1]

Group 1 - The core point of the article is that Kangpeng Technology announced a credit impairment loss and asset impairment loss totaling approximately 6.4 million yuan for the first half of 2025, which will reduce the company's pre-tax profit and owner equity accordingly [1][1][1] - For the period from January to June 2025, Kangpeng Technology's revenue composition is entirely from fine chemicals, accounting for 100% [1][1][1] - As of the report date, Kangpeng Technology has a market capitalization of 5 billion yuan [1][1][1]

Core Viewpoint - Kangpeng Technology (688602.SH) reported significant growth in both revenue and net profit for the first half of 2025, driven by its CDMO business and increased orders from downstream clients [1] Financial Performance - The company achieved operating revenue of 436 million yuan, representing a year-on-year increase of 27.94% [1] - Net profit attributable to shareholders reached 31.02 million yuan, showing a substantial year-on-year growth of 257.08% [1] - The net profit after deducting non-recurring gains and losses was 23.36 million yuan, marking a turnaround from losses in the previous period [1] - Basic earnings per share were reported at 0.06 yuan [1] Business Segment Performance - The notable revenue growth was primarily attributed to the CDMO business, which experienced significant growth due to industry trends and the order cycle from downstream clients [1]

上海康鹏科技股份有限公司 2025 年上半年公司营业收入 4.36 亿元，同比上升 27.94%；归属于上市公司 股东的净利润 0.31 亿元，同比增加 257.08%；归属于上市公司股东的扣除非经 常性损益的净利润 0.23 亿元，较上年同期实现了扭亏为盈。 报告期内公司新材料板块毛利率小幅下调，主要系电池材料部分原料碳酸 锂的市场价格在上一年度持续下降，从而在本报告期内处于相对低位，产品价 格进一步下降。公司医药类产品的毛利率水平和整体销售规模均有上升，除受 下游客户订单周期影响外，公司在深化与跨国药企合作的同时，也在积极参与 展会。公司上半年在中国（上海）国际农药化学品及植保展览会（CAC 展）、 第二十三届世界制药原料中国展（CPHI China 2025），与多家潜在客户深入交 谈，不断开拓新客户。随着本年切入多肽新赛道以及境外医药客户新药上市影 响，公司将努力在创新药产业链中占据高附加值环节。 二、加快发展新质生产力 为应对市场客户需求与市场竞争状况不断演变的特点，公司根据市场变化 和产品发展趋势确定募集资金投入节奏，将项目实施周期拉长并出于审慎考虑 调减投入，并将资源投入到液晶项目的产能整合、其 ...

证券代码：688602 证券简称：康鹏科技 公告编号：2025-047 上海康鹏科技股份有限公司 关于 2025 年半年度募集资金存放与实际使用情况 的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会（以下简称"中国证监会"）印发的《上市公 司募集资金监管规则》（证监会公告[2025]10号）、《上海证券交易所科创板上 市公司自律监管指引第1号——规范运作》等相关法律法规的规定及要求，上海 康鹏科技股份有限公司（以下简称"公司"、"本公司"或"康鹏科技"）董事会将公 司2025半年度募集资金存放与实际使用情况专项说明如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 根据中国证监会于2023年5月9日出具的《关于同意上海康鹏科技股份有限 公司首次公开发行股票注册的批复》（证监许可 [2023] 1007号）（以下简称"首 次公开发行"），公司获准向社会公开发行人民币普通股103,875,000股，每股面 值为人民币1.00元，每股发行价格为人民币8.66元，募集资金总额为 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688602 证券简称：康鹏科技 公告编号：2025-049 上海康鹏科技股份有限公司 关于 2025 年半年度计提资产减值准备的公告 二、计提减值准备事项的具体说明 三、计提资产减值准备对公司的影响 一、 计提资产减值准备情况概述 根据《企业会计准则第 8 号——资产减值》及上海康鹏科技股份有限公司（以 下简称"公司"）会计政策、会计估计的相关规定，为客观、公允地反映公司截 至 2025 年 6 月 30 日的财务状况，经公司及下属子公司对应收账款、其他应收款、 存货等进行全面充分的评估和分析，认为上述资产中部分资产存在一定的减值迹 象，遵循谨慎性原则，公司对相关资产进行了减值测试并计提了相应的减值准备。 公司 2025 年上半年计提的各项减值损失总额为 6,402,051.51 元。具体情况如下 表所示： 单位：元 | 项目 | 2025年1-6月 计提及转回金额 | 备注 | | --- | --- | --- | | 信用减值损失 | 1,178,340.1 ...

```markdown [Important Notice](index=2&type=section&id=%E9%87%8D%E8%A6%81%E6%8F%90%E7%A4%BA) [Board of Directors' Statement](index=2&type=section&id=%E4%B8%80%E3%80%81%20%E6%9C%AC%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E4%BC%9A%E5%8F%8A%E8%91%A3%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E4%BF%9D%E8%AF%81%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E5%86%85%E5%AE%B9%E7%9A%84%E7%9C%9F%E5%AE%9E%E6%80%A7%E3%80%81%E5%87%86%E7%A1%AE%E6%80%A7%E3%80%81%E5%AE%8C%E6%95%B4%E6%80%A7%EF%BC%8C%E4%B8%8D%E5%AD%98%E5%9C%A8%E8%99%9A%E5%81%87%E8%AE%B0%E8%BD%BD%E3%80%81%E8%AF%AF%E5%AF%BC%E6%80%A7%E9%99%88%E8%BF%B0%E6%88%96%E9%87%8D%E5%A4%A7%E9%81%97%E6%BC%8F%EF%BC%8C%E5%B9%B6%E6%89%BF%E6%8B%85%E4%B8%AA%E5%88%AB%E5%92%8C%E8%BF%9E%E5%B8%A6%E7%9A%84%E6%B3%95%E5%BE%8B%E8%B4%A3%E4%BB%BB%E3%80%82) The company's board of directors and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content, assuming individual and joint legal responsibility - The company's board of directors and senior management guarantee the truthfulness, accuracy, and completeness of the semi-annual report content, assuming legal responsibility[3](index=3&type=chunk) [Significant Risk Warning](index=2&type=section&id=%E4%BA%8C%E3%80%81%20%E9%87%8D%E5%A4%A7%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The report details potential risks in the company's operations; please refer to "Section III Management Discussion and Analysis" for specific risk factors - The company has detailed operational risks in the report; specific content can be found in "Section III Management Discussion and Analysis", "IV. Risk Factors"[3](index=3&type=chunk) [Audit Status](index=2&type=section&id=%E5%9B%9B%E3%80%81%20%E6%9C%AC%E5%8D%8A%E5%B9%B4%E5%BA%A6%E6%8A%A5%E5%91%8A%E6%9C%AA%E7%BB%8F%E5%AE%A1%E8%AE%A1%E3%80%82) This semi-annual report is unaudited - This semi-annual report is unaudited[4](index=4&type=chunk) [Forward-Looking Statements Risk Disclaimer](index=2&type=section&id=%E5%85%AB%E3%80%81%20%E5%89%8D%E7%9E%BB%E6%80%A7%E9%99%88%E8%BF%B0%E7%9A%84%E9%A3%8E%E9%99%A9%E5%A3%B0%E6%98%8E) Forward-looking statements in the report, such as future plans and development strategies, do not constitute substantial commitments; investors should exercise caution and be aware of investment risks - Forward-looking statements in the report, including future plans and development strategies, do not constitute substantial commitments to investors; investors should exercise caution and be aware of investment risks[5](index=5&type=chunk) [Section I Definitions](index=4&type=section&id=%E7%AC%AC%E4%B8%80%E8%8A%82%20%E9%87%8A%E4%B9%89) [Section II Company Profile and Key Financial Indicators](index=4&type=section&id=%E7%AC%AC%E4%BA%8C%E8%8A%82%20%E5%85%AC%E5%8F%B8%E7%AE%80%E4%BB%8B%E5%92%8C%E4%B8%BB%E8%A6%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) [Company's Basic Information](index=4&type=section&id=%E4%B8%80%E3%80%81%20%E5%85%AC%E5%8F%B8%E5%9F%BA%E6%9C%AC%E6%83%85%E5%86%B5) This section introduces Shanghai Chemspec Corporation's basic information, including its Chinese and English names, registered address, legal representative, website, and email Company Basic Information | 指标 | 内容 | | :--- | :--- | | 中文名称 | 上海康鹏科技股份有限公司 | | 中文简称 | 康鹏科技 | | 外文名称 | ShanghaiChemspecCorporation | | 外文名称缩写 | Chemspec | | 法定代表人 | 杨建华 | | 注册地址 | 上海市普陀区祁连山南路2891弄200号1幢 | | 公司网址 | https://www.chemspec.com.cn | | 电子信箱 | ir@chemspec.com.cn | [Contact Person and Information](index=5&type=section&id=%E4%BA%8C%E3%80%81%20%E8%81%94%E7%B3%BB%E4%BA%BA%E5%92%8C%E8%81%94%E7%B3%BB%E6%96%B9%E5%BC%8F) This section provides contact information for the company's Board Secretary (domestic representative for information disclosure), including name, address, phone, fax, and email Board Secretary Contact Information | 姓名 | 张熙 | | :--- | :--- | | 联系地址 | 上海市普陀区祁连山南路2891弄200号1幢 | | 电话 | 021-63638712 | | 传真 | 021-63636993 | | 电子信箱 | ir@chemspec.com.cn | [Information Disclosure and Document Custody Location Changes](index=5&type=section&id=%E4%B8%89%E3%80%81%20%E4%BF%A1%E6%81%AF%E6%8A%AB%E9%9C%B2%E5%8F%8A%E5%A4%87%E7%BD%AE%E5%9C%B0%E7%82%B9%E5%8F%98%E6%9B%B4%E6%83%85%E5%86%B5%E7%AE%80%E4%BB%8B) The company designates four newspapers for information disclosure, publishes the semi-annual report on the Shanghai Stock Exchange website, and keeps it at the company's Board Office Information Disclosure Channels | 信息披露报纸名称 | 《中国证券报》、《证券日报》、《上海证券报》、《证券时报》 | | :--- | :--- | | 登载半年度报告的网站地址 | www.sse.com.cn | | 公司半年度报告备置地点 | 上海康鹏科技股份有限公司董事会办公室 | [Company Stock/Depositary Receipt Summary](index=5&type=page&id=%E5%9B%9B%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E7%A5%A8%2F%E5%AD%98%E6%89%98%E5%87%AD%E8%AF%81%E7%AE%80%E5%86%B5) The company's A-shares are listed on the STAR Market of the Shanghai Stock Exchange, with stock abbreviation Chemspec and stock code 688602 Company Stock Summary | 股票种类 | 股票上市交易所及板块 | 股票简称 | 股票代码 | | :--- | :--- | :--- | :--- | | A股 | 上海证券交易所科创板 | 康鹏科技 | 688602 | [Company's Key Accounting Data and Financial Indicators](index=6&type=section&id=%E5%85%AD%E3%80%81%E5%85%AC%E5%8F%B8%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) In H1 2025, the company's operating revenue increased by **27.94%** year-on-year, total profit and net profit attributable to parent company significantly grew to **34.74 million yuan** and **31.01 million yuan** respectively, and net cash flow from operating activities increased by **197.20%** Key Accounting Data (Jan-Jun 2025) | 指标 | 本报告期（1-6月） | 上年同期 | 本报告期比上年同期增减(%) | | :--- | :--- | :--- | :--- | | 营业收入 | 436,438,594.81 yuan | 341,123,272.46 yuan | 27.94 % | | 利润总额 | 34,741,118.74 yuan | 5,432,061.75 yuan | 539.56 % | | 归属于上市公司股东的净利润 | 31,016,753.93 yuan | 8,686,215.75 yuan | 257.08 % | | 归属于上市公司股东的扣除非经常性损益的净利润 | 23,362,820.17 yuan | -30,780,342.00 yuan | 不适用 | | 经营活动产生的现金流量净额 | 77,644,713.68 yuan | 26,125,232.34 yuan | 197.20 % | | 归属于上市公司股东的净资产（期末） | 2,809,906,363.62 yuan | 2,772,109,591.34 yuan | 1.36 % | | 总资产（期末） | 3,244,838,769.04 yuan | 3,255,092,762.50 yuan | -0.32 % | Key Financial Indicators (Jan-Jun 2025) | 指标 | 本报告期（1-6月） | 上年同期 | 本报告期比上年同期增减(%) | | :--- | :--- | :--- | :--- | | 基本每股收益（元／股） | 0.06 yuan/share | 0.02 yuan/share | 200.00 % | | 稀释每股收益（元／股） | 0.06 yuan/share | 0.02 yuan/share | 200.00 % | | 扣除非经常性损益后的基本每股收益（元／股） | 0.04 yuan/share | -0.06 yuan/share | 不适用 | | 加权平均净资产收益率（%） | 1.11 % | 0.31 % | 增加 0.80 percentage points | | 扣除非经常性损益后的加权平均净资产收益率（%） | 0.84 % | -1.10 % | 增加 1.94 percentage points | | 研发投入占营业收入的比例（%） | 8.28 % | 11.80 % | 减少 3.52 percentage points | [Differences in Accounting Data Under Domestic and Overseas Accounting Standards](index=6&type=section&id=%E4%B8%83%E3%80%81%E5%A2%83%E5%86%85%E5%A4%96%E4%BC%9A%E8%AE%A1%E5%87%86%E5%88%99%E4%B8%8B%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%B7%AE%E5%BC%82) The company's growth in operating revenue, total profit, net profit, and EPS is primarily due to significant CDMO business growth and cost rigidity, with increased overseas customer payments also boosting net cash flow from operating activities - Operating revenue increased by **27.94%** year-on-year during the reporting period, mainly due to significant growth in the CDMO business influenced by industry and downstream customer order cycles[20](index=20&type=chunk) - Total profit, net profit attributable to shareholders of the listed company, and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses significantly increased, mainly due to revenue growth and cost rigidity[20](index=20&type=chunk) - Net cash flow from operating activities increased, primarily due to a substantial year-on-year increase in cash flow from operating activities during the reporting period, driven by increased overseas customer payments in the first half[20](index=20&type=chunk) [Non-Recurring Gains and Losses Items and Amounts](index=7&type=section&id=%E5%85%AB%E3%80%81%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) The company's total non-recurring gains and losses for H1 2025 amounted to **7.6539 million yuan**, primarily including government subsidies, fair value changes in financial assets, and disposal gains/losses of non-current assets Non-Recurring Gains and Losses Items and Amounts (Jan-Jun 2025) | 非经常性损益项目 | 金额 (元) | | :--- | :--- | | 非流动性资产处置损益 | 111,746.38 | | 计入当期损益的政府补助 | 6,698,226.42 | | 非金融企业持有金融资产和金融负债产生的公允价值变动损益以及处置金融资产和金融负债产生的损益 | 2,804,467.27 | | 除上述各项之外的其他营业外收入和支出 | -626,844.30 | | 减：所得税影响额 | 1,333,796.95 | | 少数股东权益影响额（税后） | -134.94 | | **合计** | **7,653,933.76** | [Net Profit After Deducting Share-Based Payment Impact](index=8&type=section&id=%E4%B9%9D%E3%80%81%E5%AD%98%E5%9C%A8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E7%9A%84%E5%85%AC%E5%8F%B8%E5%8F%AF%E9%80%89%E6%8B%A9%E6%8A%AB%E9%9C%B2%E6%89%A3%E9%99%A4%E8%82%A1%E4%BB%BD%E6%94%AF%E4%BB%98%E5%BD%B1%E5%93%8D%E5%90%8E%E7%9A%84%E5%87%80%E5%88%A9%E6%B6%A6) The company's net profit after deducting share-based payment impact for H1 2025 was **38.1105 million yuan**, a year-on-year increase of **175.78%** Net Profit After Deducting Share-Based Payment Impact | 主要会计数据 | 本报告期（1-6月） | 上年同期 | 本期比上年同期增减(%) | | :--- | :--- | :--- | :--- | | 扣除股份支付影响后的净利润 | 38,110,512.18 yuan | 13,819,036.29 yuan | 175.78 % | [Section III Management Discussion and Analysis](index=8&type=section&id=%E7%AC%AC%E4%B8%89%E8%8A%82%20%E7%AE%A1%E7%90%86%E5%B1%82%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) [Company's Industry and Main Business](index=8&type=section&id=%E4%B8%80%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E5%85%AC%E5%8F%B8%E6%89%80%E5%B1%9E%E8%A1%8C%E4%B8%9A%E5%8F%8A%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E6%83%85%E5%86%B5%E8%AF%B4%E6%98%8E) The company specializes in fine chemicals, focusing on new materials and CDMO products, with new materials including display, new energy battery, and organosilicon materials, while the CDMO sector saw significant recovery in H1 2025 - In H1 2025, China's LCD market share increased to over **70%**, with domestic manufacturers reshaping the global display industry supply chain through mergers, acquisitions, and self-built capacities[25](index=25&type=chunk) - Electrolyte production increased by over **65%** year-on-year in H1 2025 due to surging new energy vehicle demand, but product prices decreased due to falling lithium carbonate prices[25](index=25&type=chunk) - The CDMO industry significantly recovered in 2025, with a moderate rebound in global biopharmaceutical investment and financing activity, and steady growth in pharmaceutical R&D investment bringing potential orders[25](index=25&type=chunk) Main Products and Uses | 产品分类 | 主要产品 | 主要产品用途 | 最终应用领域 | | :--- | :--- | :--- | :--- | | 新材料-显示材料 | 含氟液晶单体及中间体 | 混晶产品中的重要功能性液晶单体 | 液晶显示屏 | | 新材料-新能源电池材料及电子化学品 | LiFSI | 锂电池电解液的重要溶质锂盐或添加剂 | 锂离子电池 | | 新材料-有机硅材料 | 有机硅压敏胶 | 耐高温的遮蔽带 | 半导体电路板、白色家电、汽车等 | | 新材料-有机硅材料 | 苯基有机硅产品 | 苯基硅烷，苯基硅油，苯基硅橡胶 | LED、食品、电力、航空航天等 | | CDMO-医药 | 创新药的原料药或中间体的定制开发 | 医药重要原料 | 医疗健康 | | CDMO-农药 | 新型杀虫剂、杀菌剂、除螨剂等创新型的原药或中间体的定制开发 | 农药重要原料 | 植保领域 | [Discussion and Analysis of Operations](index=10&type=section&id=%E4%BA%8C%E3%80%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5%E7%9A%84%E8%AE%A8%E8%AE%BA%E4%B8%8E%E5%88%86%E6%9E%90) In the first half, the company achieved stable profitability and turned its net profit attributable to parent company after deducting non-recurring gains and losses into profit by focusing on core businesses, optimizing product lines, and strengthening customer relationships, while also adjusting fundraising projects and implementing equity incentive plans - In H1 2025, the company's operating revenue was **436 million yuan**, net profit attributable to shareholders of the listed company was **31 million yuan**, and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was **23 million yuan**, achieving a turnaround to profit[31](index=31&type=chunk) - Profitability improvement primarily benefited from increased shipments of high-margin pharmaceutical products, significant growth in the CDMO segment, and the company's comprehensive implementation of cost optimization and efficiency improvement measures[31](index=31&type=chunk) - The company changed its fundraising projects, reducing some investments and reallocating resources to LCD project capacity integration, other electronic chemical businesses, and peptide API business expansion to create new performance growth points[31](index=31&type=chunk) - The company granted **712,000** restricted shares of the second category to **55** incentive recipients, efficiently implementing the equity incentive plan to retain and motivate core talent and enhance team cohesion[32](index=32&type=chunk) [Core Competitiveness Analysis](index=10&type=section&id=%E4%B8%89%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E6%A0%B8%E5%BF%83%E7%AB%9E%E4%BA%89%E5%8A%9B%E5%88%86%E6%9E%90) The company's core competitiveness lies in its comprehensive R&D system, significant technological advantages, stable customer relationships, and strict quality control, holding **106** national patents and being recognized as a single-champion product for LiFSI and a national "Little Giant" enterprise - The company has a comprehensive R&D system, with four R&D groups, an engineering technology center, and an analysis center responsible for R&D of display materials, new energy battery materials, pharmaceutical, and pesticide products, and has established a management incentive system[33](index=33&type=chunk) - As of the end of the reporting period, the company and its subsidiaries had accumulated **106** national patents (**67** invention patents, **39** utility model patents), possessing strong process development and production capabilities in the fluorinated fine chemical field[33](index=33&type=chunk)[37](index=37&type=chunk) - The company has established long-term stable cooperative relationships with global industry-leading customers based on its strong technical capabilities, strict EHS and quality assurance systems, stable and excellent product quality, and good delivery records[34](index=34&type=chunk) - The company's QA/QC department draws on advanced quality management concepts from excellent overseas enterprises, implementing full-process inspection control from raw materials to final products to ensure stable product quality[34](index=34&type=chunk)[35](index=35&type=chunk) National Recognition Status | 认定主体 | 认定称号 | 认定年度 | 产品名称 | | :--- | :--- | :--- | :--- | | 上海康鹏科技股份有限公司 | 单项冠军产品 | 2024-2026 | 双氟磺酰亚胺锂盐（LiFSI） | | 上海万溯药业有限公司 | 国家级专精特新“小巨人”企业 | 2022-2025 | 不适用 | [Comprehensive R&D System and Strong R&D Capabilities](index=10&type=section&id=1.%E7%A0%94%E5%8F%91%E4%BD%93%E7%B3%BB%E5%AE%8C%E5%96%84%EF%BC%8C%E7%A0%94%E5%8F%91%E8%83%BD%E5%8A%9B%E5%BC%BA) The company's R&D technology center comprises four R&D groups, an engineering technology center, and an analysis center, each responsible for different product lines, supported by a comprehensive management and incentive system - The company's R&D technology center undertakes technological innovation, with four R&D groups (display materials, new energy battery materials and electronic chemicals, pharmaceutical products, and pesticide products), an engineering technology center, and an analysis center[33](index=33&type=chunk) - The company has established a series of systems for managing and incentivizing scientific research projects, covering project initiation, management, assessment, rewards, and patent applications[33](index=33&type=chunk) [Significant Technological Advantages and Strong Technical Reserves](index=10&type=section&id=2.%E6%8A%80%E6%9C%AF%E4%BC%98%E5%8A%BF%E6%98%BE%E8%91%97%EF%BC%8C%E6%8A%80%E6%9C%AF%E5%82%A8%E5%A4%87%E9%9B%84%E5%8E%9A) As of the end of the reporting period, the company and its subsidiaries had accumulated **106** national patents, protecting core technologies through confidentiality, and possess strong process development and production capabilities in fluorinated fine chemicals - As of the end of the reporting period, the company and its subsidiaries had accumulated **106** national patents, with comprehensive and strict protection of core technologies through technical confidentiality systems and agreements[33](index=33&type=chunk) - The company has continuously deepened its expertise in the fluorinated fine chemical field for many years, optimizing product structures and production processes, and possesses strong process development and production capabilities[33](index=33&type=chunk) [Stable Customer Cooperation](index=10&type=section&id=3.%E5%AE%A2%E6%88%B7%E5%90%88%E4%BD%9C%E7%A8%B3%E5%AE%9A) The company has established long-term stable cooperative relationships with numerous global industry-leading customers, leveraging its strong technical capabilities, strict EHS and quality assurance systems, stable product quality, and excellent delivery record - The company has established long-term stable cooperative relationships by passing the strict supplier system audits of global industry-leading customers[34](index=34&type=chunk) - The company relies on its strong technical capabilities, strict EHS and quality assurance systems, stable and excellent product quality, and good delivery records[34](index=34&type=chunk) [Comprehensive Quality Control System and Stable Product Quality](index=10&type=section&id=4.%E5%93%81%E6%8E%A7%E4%BD%93%E7%B3%BB%E5%AE%8C%E5%96%84%EF%BC%8C%E4%BA%A7%E5%93%81%E8%B4%A8%E9%87%8F%E7%A8%B3%E5%AE%9A) The company's QA/QC department, drawing on advanced overseas quality management concepts, implements full-process inspection control from raw materials to final products, supported by advanced testing instruments, ensuring product quality stability, with subsidiaries certified with ISO9001 and ISO14001 - The company's QA/QC department draws on advanced quality management concepts from excellent overseas enterprises, implementing full-process inspection control at every critical stage from raw materials, intermediates to final products[34](index=34&type=chunk) - The company enhances detection accuracy with a series of advanced testing instruments, such as gas chromatograph-mass spectrometers, liquid chromatograph-mass spectrometers, and ion chromatographs, ensuring high-quality and reliable products[34](index=34&type=chunk)[35](index=35&type=chunk) - Subsidiaries Shanghai Wansu, Zhejiang Huajing, and Quzhou Chemspec have all passed ISO9001 quality management system certification and ISO14001 environmental management system certification[35](index=35&type=chunk) [Core Technologies and R&D Progress](index=11&type=section&id=(%E4%B8%89)%20%E6%A0%B8%E5%BF%83%E6%8A%80%E6%9C%AF%E4%B8%8E%E7%A0%94%E5%8F%91%E8%BF%9B%E5%B1%95) The company's core technologies remained largely unchanged, with **1** new invention patent and **1** utility model patent granted during the reporting period, totaling **106** effective patents; R&D investment decreased by **10.26%** year-on-year, and its proportion to operating revenue decreased by **3.52** percentage points, with ongoing R&D projects across various material and intermediate fields - The company's core technologies and their advanced nature remained unchanged during the reporting period[36](index=36&type=chunk) Intellectual Property Acquired During the Reporting Period | 类别 | 本期新增申请数（个） | 本期新增获得数（个） | 累计申请数（个） | 累计获得数（个） | | :--- | :--- | :--- | :--- | :--- | | 发明专利 | 5 | 1 | 22 | 67 | | 实用新型专利 | 6 | 1 | 6 | 39 | | 软件著作权 | - | - | - | 23 | | 合计 | 11 | 2 | 28 | 129 | R&D Investment Status | 指标 | 本期数 (元) | 上年同期数 (元) | 变化幅度（%） | | :--- | :--- | :--- | :--- | | 费用化研发投入 | 36,130,378.40 | 40,260,470.42 | -10.26 | | 研发投入合计 | 36,130,378.40 | 40,260,470.42 | -10.26 | | 研发投入总额占营业收入的比例（%） | 8.28 | 11.80 | 减少 3.52 percentage points | - The company has ongoing R&D projects in liquid crystal materials, OLED materials, new energy battery materials, other materials, organosilicon materials, pharmaceutical intermediates and APIs, and pesticide intermediates and APIs, aiming to optimize processes, reduce costs, improve quality, and expand application prospects[38](index=38&type=chunk)[39](index=39&type=chunk) [Risk Factors](index=14&type=section&id=%E5%9B%9B%E3%80%81%E9%A3%8E%E9%99%A9%E5%9B%A0%E7%B4%A0) The company faces risks including customer concentration, continuous product price declines, changes in trade policies, and substantial depreciation from new fixed assets; display materials and CDMO businesses rely on specific customers, LiFSI product prices are falling, overseas revenue is sensitive to trade policies, and large fixed asset investments may lead to profit decline - The company faces customer concentration risk, with display materials business relying on Nakamura Japan and CDMO business relying on Soda Japan[43](index=43&type=chunk) - The price of LiFSI products in new energy battery materials and electronic chemicals is trending downwards, which may adversely affect operating revenue and profit levels[43](index=43&type=chunk) - The company has a high proportion of overseas revenue, and overseas sales are affected by unfavorable changes in political and economic situations and trade policies[43](index=43&type=chunk) - The company has a large scale of new fixed asset depreciation, and the capitalization of fundraising projects may significantly impact operating performance, posing a risk of profit decline due to increased depreciation[43](index=43&type=chunk) [Key Operating Performance](index=14&type=section&id=%E4%BA%94%E3%80%81%E6%8A%A5%E5%91%8A%E6%9C%9F%E5%86%85%E4%B8%BB%E8%A6%81%E7%BB%8F%E8%90%A5%E6%83%85%E5%86%B5) During the reporting period, the company achieved operating revenue of **436 million yuan**, net profit attributable to shareholders of the listed company of **31 million yuan**, and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of **23 million yuan** - During the reporting period, the company achieved operating revenue of **436 million yuan**, net profit attributable to shareholders of the listed company of **31 million yuan**, and net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses of **23 million yuan**[44](index=44&type=chunk) [Main Business Analysis](index=14&type=section&id=(%E5%9B%9B)%20%E4%B8%BB%E8%90%A5%E4%B8%9A%E5%8A%A1%E5%88%86%E6%9E%90) During the reporting period, the company's operating revenue increased by **27.94%** year-on-year, primarily due to significant CDMO business growth; net cash flow from operating activities substantially increased by **197.20%** due to increased overseas customer payments, while investment and financing cash flow changes were influenced by short-term wealth management and loan rollover timings Financial Statement Related Items Fluctuation Analysis | 科目 | 本报告期 (元) | 上年同期 (元) | 变动比例 (%) | | :--- | :--- | :--- | :--- | | 营业收入 | 436,438,594.81 | 341,123,272.46 | 27.94 | | 营业成本 | 336,540,767.24 | 284,547,542.72 | 18.27 | | 销售费用 | 5,711,010.01 | 5,368,414.28 | 6.38 | | 管理费用 | 35,675,032.00 | 38,996,250.65 | -8.52 | | 财务费用 | -6,543,916.30 | -5,487,088.59 | 不适用 | | 研发费用 | 36,130,378.40 | 40,260,470.42 | -10.26 | | 经营活动产生的现金流量净额 | 77,644,713.68 | 26,125,232.34 | 197.20 | | 投资活动产生的现金流量净额 | 205,789,947.89 | -652,988,078.36 | 不适用 | | 筹资活动产生的现金流量净额 | -38,801,580.76 | -29,380,751.41 | 不适用 | - Operating revenue increased by **27.94%** year-on-year, mainly due to significant growth in the CDMO business influenced by industry and downstream customer order cycles this year[47](index=47&type=chunk) - Net cash flow from operating activities significantly increased year-on-year, primarily due to increased overseas customer payments in the first half[47](index=47&type=chunk) - Changes in net cash flow from investing activities were influenced by the frequency of short-term wealth management investments and different maturity dates[47](index=47&type=chunk) - Changes in net cash flow from financing activities were mainly affected by the timing of loan rollovers during the reporting period[47](index=47&type=chunk) [Assets and Liabilities Analysis](index=15&type=section&id=(%E5%85%AD)%20%E8%B5%84%E4%BA%A7%E3%80%81%E8%B4%9F%E5%80%BA%E6%83%85%E5%86%B5%E5%88%86%E6%9E%90) At the end of the reporting period, the company's asset and liability structure saw multiple changes, including increases in notes receivable and accounts payable, decreases in accounts receivable financing, short-term borrowings, and contract liabilities, a significant increase in right-of-use assets and lease liabilities due to renewed contracts, with overseas assets accounting for **2.00%** of total assets, and restricted assets totaling **91.376 million yuan** Assets and Liabilities Fluctuation (Period-end vs. Previous Year-end) | 项目名称 | 本期期末数 (元) | 本期期末数占总资产的比例 (%) | 上年期末数 (元) | 上年期末数占总资产的比例 (%) | 较上年期末变动比例 (%) | 情况说明 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 应收票据 | 40,247,246.90 | 1.24 | 29,555,563.62 | 0.91 | 36.17 | 报告期末客户以票据支付增加 | | 应收款项融资 | 5,697,122.08 | 0.18 | 12,836,494.22 | 0.39 | -55.62 | 报告期末购销以票据结算减少 | | 投资性房地产 | 2,914,675.28 | 0.09 | 5,355,011.79 | 0.16 | -45.57 | 报告期内部分厂房取消对外租赁 | | 使用权资产 | 30,219,442.46 | 0.93 | 4,556,588.88 | 0.14 | 563.20 | 报告期内租赁合同更新期限影响 | | 短期借款 | 60,178,886.09 | 1.85 | 88,448,694.43 | 2.72 | -31.96 | 报告期内1年以内流动资金借款减少 | | 应付票据 | 18,000,000.00 | 0.55 | 45,000,000.00 | 1.38 | -60.00 | 报告期末开与供应商票据结算减少 | | 应付账款 | 86,228,657.50 | 2.66 | 57,353,185.53 | 1.76 | 50.35 | 报告期末供应商应付款增加 | | 合同负债 | 11,957,446.03 | 0.37 | 19,163,426.34 | 0.59 | -37.60 | 报告期末收到的预收账款减少 | | 一年内到期的非流动负债 | 12,631,236.50 | 0.39 | 2,358,947.48 | 0.07 | 435.46 | 报告期末将到期的长期借款及租赁负债增加 | | 租赁负债 | 18,646,675.32 | 0.57 | 3,242,244.14 | 0.10 | 475.12 | 报告期内承租物业租期到期日影响 | - Overseas assets amounted to **64,805,342.58 yuan**, accounting for **2.00%** of total assets[51](index=51&type=chunk) Main Restricted Assets | 项目 | 账面余额 (元) | 账面价值 (元) | 受限类型 | | :--- | :--- | :--- | :--- | | 货币资金 | 800.00 | 800.00 | 保证金 | | 固定资产 | 115,409,291.34 | 69,454,977.20 | 借款抵押保证 | | 无形资产 | 27,908,391.19 | 21,920,223.94 | 借款抵押保证 | | 合计 | 143,318,482.53 | 91,376,001.14 | / | [Investment Status Analysis](index=18&type=section&id=(%E4%B8%83)%20%E6%8A%95%E8%B5%84%E7%8A%B6%E5%86%B5%E5%88%86%E6%9E%90) During the reporting period, the company's investment activities primarily involved financial assets measured at fair value and derivative investments; purchases and sales of financial assets measured at fair value both amounted to **723 million yuan**, with a fair value change gain of **2.8045 million yuan**; derivative investments, mainly foreign currency swaps, generated a gain of **21,500 yuan**, with the company managing exchange rate risks through self-selected settlement and short-term currency swaps Changes in Financial Assets Measured at Fair Value | 资产类别 | 本期公允价值变动损益 (元) | 本期购买金额 (元) | 本期出售/赎回金额 (元) | | :--- | :--- | :--- | :--- | | 其他（其中：银行理财） | 2,804,467.27 | 723,000,000.00 | 723,000,000.00 | Derivative Investment Status (for Hedging Purposes) | 衍生品投资类型 | 本期公允价值变动损益 (万元) | 报告期内购入金额 (万元) | 报告期内售出金额 (万元) | | :--- | :--- | :--- | :--- | | 外汇货币互换 | 2.15 | 1,435.20 | 1,435.20 | | 合计 | 2.15 | 1,435.20 | 1,435.20 | - A gain of **21,500 yuan** was achieved during the reporting period. The company independently chooses the timing for foreign exchange settlement to reduce exchange losses, with exchange gains of **2.3537 million yuan** in the first half, and obtained a small amount of interest income through short-term currency swap transactions with commercial banks during the period[59](index=59&type=chunk) [Analysis of Major Holding and Participating Companies](index=20&type=section&id=(%E4%B9%9D)%20%E4%B8%BB%E8%A6%81%E6%8E%A7%E8%82%A1%E5%8F%82%E8%82%A1%E5%85%AC%E5%8F%B8%E5%88%86%E6%9E%90) The company's main subsidiaries, including Shanghai Wansu, Quzhou Chemspec, Lanzhou Chemspec, and API, Inc., are involved in chemical product manufacturing and sales, with Shanghai Wansu and API, Inc. being profitable, while Quzhou Chemspec and Lanzhou Chemspec incurred losses; among associates, Zhongxiao Chemspec showed strong profitability, while Zhongke Kangrun was in a loss-making state; the company also established a wholly-owned subsidiary, Chemspec Singapore, during the reporting period Major Subsidiary Information (Unit: 10,000 yuan) | 公司名称 | 公司类型 | 主要业务 | 注册资本 | 总资产 | 净资产 | 营业收入 | 营业利润 | 净利润 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 上海万溯 | 子公司 | 化工产品生产及销售 | 14,880.00 | 35,481.27 | 30,170.40 | 7,930.01 | 15.09 | 121.21 | | 衢州康鹏 | 子公司 | 化工产品生产及销售 | 18,600.00 | 45,617.22 | 30,716.68 | 7,369.72 | -1,519.50 | -1,044.26 | | 兰州康鹏 | 子公司 | 化工产品生产及销售 | 25,000.00 | 84,433.23 | 22,999.61 | 12,723.45 | -2,153.35 | -1,822.87 | | API,Inc. | 子公司 | 化工产品生产及销售 | 60.28 (美元) | 6,480.53 | 4,760.26 | 2,117.51 | 1,032.93 | 742.57 | Information on Associate Companies with Over 10% Impact on Company's Net Profit (Unit: 10,000 yuan) | 公司名称 | 公司类型 | 主要业务 | 注册资本 | 总资产 | 净资产 | 营业收入 | 营业利润 | 净利润 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 中硝康鹏 | 参股公司 | 化工产品生产及销售 | 1,800.00 (美元) | 25,113.24 | 22,395.93 | 10,279.38 | 3,595.52 | 3,088.52 | | 中科康润 | 参股公司 | 化工产品生产及销售 | 14,328.89 | 31,848.09 | 30,601.28 | 584.79 | -1,751.03 | -1,310.42 | - During the reporting period, the company established a wholly-owned subsidiary, Chemspec Singapore, which has not yet officially commenced operations[64](index=64&type=chunk) [Section IV Corporate Governance, Environment, and Society](index=22&type=section&id=%E7%AC%AC%E5%9B%9B%E8%8A%82%20%E5%85%AC%E5%8F%B8%E6%B2%BB%E7%90%86%E3%80%81%E7%8E%AF%E5%A2%83%E5%92%8C%E7%A4%BE%E4%BC%9A) [Changes in Directors, Senior Management, and Core Technical Personnel](index=22&type=section&id=%E4%B8%80%E3%80%81%E5%85%AC%E5%8F%B8%E8%91%A3%E4%BA%8B%E3%80%81%E9%AB%98%E7%BA%A7%E7%AE%A1%E7%90%86%E4%BA%BA%E5%91%98%E5%92%8C%E6%A0%B8%E5%BF%83%E6%8A%80%E6%9C%AF%E4%BA%BA%E5%91%98%E5%8F%98%E5%8A%A8%E6%83%85%E5%86%B5) During the reporting period, the company's board of directors and supervisory board underwent re-election, with Jia Xiling, Wang Yue, LUSHOUFU, and Xi Ping elected as third-term board members, Peng Guangrong and Cui Yongtao appointed as Deputy General Managers, and Zhang Xi appointed as Board Secretary, while several former independent directors, directors, and supervisors resigned - Jia Xiling, Wang Yue, LUSHOUFU, and Xi Ping were approved as members of the third Board of Directors at the first extraordinary general meeting of shareholders in 2025[68](index=68&type=chunk) - Qi Weinan resigned due to the re-election of the supervisory board; Dong Hui, Chen Daisong, SUN Yun George, Liu Lei, and Yang Chongbo resigned due to the re-election of the board of directors; Fan Zhuhui, Li Yan, and Feng Jianwei were dismissed due to the cancellation of the supervisory board approved at the 2024 annual general meeting of shareholders[68](index=68&type=chunk) - Peng Guangrong and Cui Yongtao were appointed as Deputy General Managers by the second meeting of the third Board of Directors, and Zhang Xi was appointed as Board Secretary by the first meeting of the third Board of Directors[68](index=68&type=chunk)[70](index=70&type=chunk) [Profit Distribution or Capital Reserve Conversion Plan](index=22&type=section&id=%E4%BA%8C%E3%80%81%E5%88%A9%E6%B6%A6%E5%88%86%E9%85%8D%E6%88%96%E8%B5%84%E6%9C%AC%E5%85%AC%E7%A7%AF%E9%87%91%E8%BD%AC%E5%A2%9E%E9%A2%84%E6%A1%88) The company has no profit distribution plan or capital reserve conversion to share capital plan for this semi-annual report - The company has no profit distribution plan or capital reserve conversion to share capital plan for this semi-annual report[68](index=68&type=chunk) [Equity Incentive Plan and Its Impact](index=22&type=section&id=%E4%B8%89%E3%80%81%E5%85%AC%E5%8F%B8%E8%82%A1%E6%9D%83%E6%BF%80%E5%8A%B1%E8%AE%A1%E5%88%92%E3%80%81%E5%91%98%E5%B7%A5%E6%8C%81%E8%82%A1%E8%AE%A1%E5%88%92%E6%88%96%E5%85%B6%E4%BB%96%E5%91%98%E5%B7%A5%E6%BF%80%E5%8A%B1%E6%8E%AA%E6%96%BD%E7%9A%84%E6%83%85%E5%86%B5%E5%8F%8A%E5%85%B6%E5%BD%B1%E5%93%8D) In June 2025, the company granted **712,000** restricted shares of the second category to **55** incentive recipients, aiming to motivate middle and senior management and core technical personnel, enhance team cohesion, and lay a talent foundation for future development - In H1 2025, the company granted **712,000** restricted shares of the second category to **55** incentive recipients, including middle and senior management, and core technical (business) personnel[32](index=32&type=chunk) - The equity incentive plan aims to effectively retain and motivate core talent, enhance team cohesion and combat effectiveness, and lay a solid talent foundation for the company's future continuous innovation and high-quality development[32](index=32&type=chunk) [Environmental Information Disclosure](index=23&type=section&id=%E5%9B%9B%E3%80%81%E7%BA%B3%E5%85%A5%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E4%BE%9D%E6%B3%95%E6%8A%AB%E9%9C%B2%E4%BC%81%E4%B8%9A%E5%90%8D%E5%8D%95%E7%9A%84%E4%B8%8A%E5%B8%82%E5%85%AC%E5%8F%B8%E5%8F%8A%E5%85%B6%E4%B8%BB%E8%A6%81%E5%AD%90%E5%85%AC%E5%8F%B8%E7%9A%84%E7%8E%AF%E5%A2%83%E4%BF%A1%E6%81%AF%E6%83%85%E5%86%B5) The company and its three major subsidiaries (Shanghai Wansu Pharmaceutical, Quzhou Chemspec Chemical, Lanzhou Chemspec Technology) are all included in the list of enterprises required to disclose environmental information by law, with corresponding inquiry indexes provided Enterprises Included in the List of Environmental Information Disclosure by Law | 序号 | 企业名称 | 环境信息依法披露报告的查询索引 | | :--- | :--- | :--- | | 1 | 上海万溯药业有限公司 | https://e2.sthj.sh.gov.cn/jsp/view/hjpl/index.jsp | | 2 | 衢州康鹏化学有限公司 | https://mlzj.sthjt.zj.gov.cn/eps/index/enterprise-search | | 3 | 兰州康鹏科技有限公司 | https://zwfw.sthj.gansu.gov.cn/revealPubVue | [Section V Significant Matters](index=24&type=section&id=%E7%AC%AC%E4%BA%94%E8%8A%82%20%E9%87%8D%E8%A6%81%E4%BA%8B%E9%A1%B9) [Fulfillment of Commitments](index=24&type=section&id=%E4%B8%80%E3%80%81%E6%89%BF%E8%AF%BA%E4%BA%8B%E9%A1%B9%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) The company's controlling shareholder, actual controllers, directors, senior management, and core technical personnel have strictly fulfilled commitments related to the initial public offering, including share lock-up, share price stability, fraudulent share repurchase, return enhancement measures, and profit distribution, all of which were timely and strictly fulfilled during the reporting period - The controlling shareholder and its concerted parties committed not to transfer shares within **36** months from the listing date and to extend the lock-up period by **6** months under specific share price conditions[74](index=74&type=chunk) - Actual controllers Yang Jianhua, Zha Yuezhen, and Yang Chongbo committed not to transfer shares within **36** months from the listing date and to extend the lock-up period by **6** months under specific share price conditions[75](index=75&type=chunk) - The company, controlling shareholder, directors, and senior management committed to initiating share price stabilization measures under specific conditions[79](index=79&type=chunk) - The company, controlling shareholder and its concerted parties, and actual controllers committed that the prospectus and related documents contain no false records, misleading statements, or major omissions, and assume liability for compensation[80](index=80&type=chunk) - The controlling shareholder and its concerted parties, actual controllers, and shareholders holding **5%** or more of shares committed to avoiding horizontal competition and to promptly transfer or terminate businesses if competition arises[82](index=82&type=chunk)[83](index=83&type=chunk) - The company, controlling shareholder and its concerted parties, all directors, supervisors, and senior management committed to strictly adhering to the profit distribution policy, effectively safeguarding investors' share of returns[82](index=82&type=chunk) [Significant Litigation and Arbitration Matters](index=36&type=section&id=%E4%B8%83%E3%80%81%E9%87%8D%E5%A4%A7%E8%AF%89%E8%AE%BC%E3%80%81%E4%BB%B2%E8%A3%81%E4%BA%8B%E9%A1%B9) The company's wholly-owned subsidiary, Lanzhou Chemspec, is involved in a construction contract dispute with Shanghai Tianyi Architectural Decoration Engineering Co., Ltd., with relevant details disclosed in temporary announcements - Wholly-owned subsidiary Lanzhou Chemspec is involved in a construction contract dispute with Shanghai Tianyi Architectural Decoration Engineering Co., Ltd., with relevant matters disclosed in temporary announcements[86](index=86&type=chunk) [Significant Related Party Transactions](index=36&type=section&id=%E5%8D%81%E3%80%81%E9%87%8D%E5%A4%A7%E5%85%B3%E8%81%94%E4%BA%A4%E6%98%93) During the reporting period, the company engaged in daily related party transactions totaling **17.4884 million yuan**, including sales and purchases of goods, provision of services, and leasing, with major related parties including Zhongxiao Chemspec, Jiangsu Wanxianghui, Mituo Materials, Chemspec Angbo, and Wansu Zhongchuang Daily Related Party Transactions (Unit: 10,000 yuan) | 关联交易类别 | 关联方 | 预计金额 | 报告期发生额 | | :--- | :--- | :--- | :--- | | 向关联人出售商品 | 中硝康鹏 | 500.00 | 202.09 | | 向关联人出售商品 | 江苏万祥汇 | 200.00 | 68.47 | | 向关联人出售商品 | 觅拓材料 | 500.00 | 9.56 | | 向关联人提供劳务 | 中硝康鹏 | 370.00 | 90.05 | | 向关联人提供劳务 | 康鹏昂博 | 250.00 | 23.95 | | 向关联人采购商品 | 中硝康鹏 | 1,000.00 | 144.04 | | 向关联人出租 | 中硝康鹏 | 180.00 | 64.38 | | 向关联人出租 | 康鹏昂博 | 1,250.00 | 566.75 | | 向关联人承租 | 万溯众创 | 1,200.00 | 579.55 | | **合计** | | **5,450.00** | **1,748.84** | [Significant Contracts and Their Fulfillment](index=38&type=section&id=%E5%8D%81%E4%B8%80%E3%80%81%E9%87%8D%E5%A4%A7%E5%90%88%E5%90%8C%E5%8F%8A%E5%85%B6%E5%B1%A5%E8%A1%8C%E6%83%85%E5%86%B5) During the reporting period, the company's significant contracts primarily involved leasing and major guarantees; the company renewed a property lease contract with Shanghai Wansu Zhongchuang Space Management Co., Ltd. for office, laboratory, and warehouse space at a monthly rent of **912,400 yuan** for **3** years; the company and its subsidiaries provided several joint liability guarantees for subsidiaries, with a total outstanding guarantee balance of **61.80 million yuan** at the end of the reporting period, accounting for **2.2%** of the company's net assets - In January 2025, the company signed a "Property Lease Contract" with Shanghai Wansu Zhongchuang Space Management Co., Ltd., renewing the lease for offices, laboratories, and warehouses at a monthly rent of **912,400 yuan** for a **3-year** term[91](index=91&type=chunk) - This lease addresses the company's production site needs, ensures business continuity and stability, and contributes to enhancing overall competitiveness[91](index=91&type=chunk)[92](index=92&type=chunk) Company and Its Subsidiaries' Guarantees for Subsidiaries (Unit: 10,000 yuan) | 担保方 | 被担保方 | 与上市公司关系 | 担保金额 | 担保起始日 | 担保到期日 | 担保类型 | 担保是否已经履行完毕 | | :--- | :--- | :--- | :--- | :--- | :--- | :--- | :--- | | 康鹏科技公司本部 | 兰州康鹏 | 全资子公司 | 2,000 | 2023/6/26 | 2028/6/25 | 连带责任担保 | 否 | | 康鹏科技公司本部 | 兰州康鹏 | 全资子公司 | 2,800 | 2023/6/26 | 2028/6/25 | 连带责任担保 | 是 | | 康鹏科技公司本部 | 衢州康鹏 | 全资子公司 | 2,380 | 2023/3/14 | 2026/3/14 | 连带责任担保 | 否 | | 康鹏科技公司本部 | 衢州康鹏 | 全资子公司 | 10 | 2023/3/14 | 2026/3/14 | 连带责任担保 | 是 | | 康鹏科技公司本部 | 上海启越 | 全资子公司 | 1,800 | 2025/6/16 | 2026/6/12 | 连带责任担保 | 否 | | **报告期末对子公司担保余额合计** | | | **6,180** | | | |